EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols



Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols



International Journal of Antimicrobial Agents 25(6): 469-473



This study was devised to look at trends in the microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile oncology patients. The retrospective study compared various microbiological aspects recorded for febrile oncology neutropenic patients treated with two different empirical antibiotic regimens (ceftazidime plus gentamicin during 1998-1999 and piperacillin/tazobactam plus amikacin during 2000-2002). Eighty-one bacteraemic episodes occurred in 41 patients. Overall, 132 (34 during 1998-1999 and 98 during 2000-2002) organisms were isolated: 84 (65%) Gram-negative bacteria, 39 (30%) Gram-positive bacteria and 7 (5%) fungi. Enterobacter spp. incidence decreased from 18 to 6% (P = 0.07) while the recovery rates of Gram-positive organisms increased from 24 to 32% (P = 0.4) during 2000-2002 compared with 1998-1999. MRSA were not isolated from any episode of bacteraemia. Five (18%) of the 28 Escherichia coli and Klebsiella spp. isolates were beta-lactamase producers (80% [4/5] isolated during 2000-2002). Twenty-seven of 28, 27/27, 23/28, 20/25 and 27/28 of these isolates were susceptible to imipenem, piperacillin/tazobactam, gentamicin, ceftazidime and ciprofloxacin, respectively. Thirty-two of 34 (94%) and 60/74 (81%) of the Gram-negative organisms isolated during 2000-2002 were susceptible to piperacillin/tazobactam and ceftazidime, respectively (P = 0.076). No major differences in the microbial spectrum and antibiotic susceptibilities were recorded between the two consecutive study periods. An increase in the number of extended beta-lactamase producing E. coli and Klebsiella spp. occurred during 2000-2002. All beta-lactamase producing organisms were susceptible to piperacillin/tazobactam and initial empirical therapy with piperacillin/tazobactam was more appropriate than ceftazidime to cover most of the pathogens causing bacteraemia. (c) 2005 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

(PDF emailed within 0-6 h: $19.90)

Accession: 012305178

Download citation: RISBibTeXText

PMID: 15890499

DOI: 10.1016/j.ijantimicag.2005.01.020



Related references

Bacterial spectrum and susceptibility patterns of pathogens in adult febrile neutropenic patients: a comparison between two time periods. Journal of Ayub Medical College, Abbottabad 21(4): 146-149, 2011

Trends in spectrum and susceptibility patterns of pathogens causing bacteremia in pediatric febrile neutropenic oncologic patients. International Journal of Infectious Diseases 6(Supplement 2): 2S28-2S31, June, 2002

Bacterial Spectrum, Isolation Sites and Susceptibility Patterns of Pathogens in Adult Febrile Neutropenic Cancer Patients at a Specialist Hospital in Saudi Arabia. World Journal of Oncology 5(5-6): 196-203, 2014

Review of clinical profile and bacterial spectrum and sensitivity patterns of pathogens in febrile neutropenic patients in hematological malignancies: A retrospective analysis from a single center. Indian Journal of Medical and Paediatric Oncology 34(2): 85-88, 2013

Can a single antibiotic policy for the empirical treatment of febrile neutropenic patients be used for all categories of haematology/oncology patient in the same institution?. Journal of Antimicrobial ChemoTherapy 42(5): 677-678, 1998

Characterization and Antimicrobial Susceptibility Profile of Bacteraemia Causing Pathogens Isolated from Febrile Children with and without Sickle Cell Disease in Kano, Nigeria. Mediterranean Journal of Hematology and Infectious Diseases 10(1): E2018016-E2018016, 2018

Impact of same-day antibiotic susceptibility testing on time to appropriate antibiotic treatment of patients with bacteraemia: a randomised controlled trial. European Journal of Clinical Microbiology & Infectious Diseases 34(4): 831-838, 2015

Bacteraemia risk criteria in the paediatric febrile neutropenic cancer patient. Clinical & Translational Oncology 7(4): 165-168, 2005

The outcome of febrile neutropenic episodes in paediatric oncology at the Wendy Fitzwilliam Paediatric Hospital. West Indian Medical Journal 60(2): 153-157, 2011

The spectrum of bacterial infections in febrile neutropenic patients: effect on empiric antibiotic therapy. Jpma. Journal of the Pakistan Medical Association 48(12): 364-367, 1999

Bloodstream infections in febrile neutropenic patients: bacterial spectrum and antimicrobial susceptibility pattern. Journal of Ayub Medical College, Abbottabad 16(1): 18-22, 2004

Investigation of the antibiotic susceptibility patterns of pathogens causing nosocomial infections. Saudi Medical Journal 25(10): 1403-1409, 2004

Teicoplanin in combination therapy for febrile episodes in neutropenic and non-neutropenic paediatric patients. Journal of Antimicrobial ChemoTherapy 21 Suppl A: 113-116, 1988

Prospective and comparative study of 2 antibiotic therapy protocols in 66 febrile neutropenic patients. Ceftazidime-vancomycin versus ticarcillin-vancomycin-amikacin. Presse Medicale 17(37): 1964-1967, 1988

Bacteraemia in febrile neutropenic cancer patients. International Journal of Antimicrobial Agents 30 Suppl 1: S51-S59, 2007